Josef Karban

422 total citations
31 papers, 300 citations indexed

About

Josef Karban is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Josef Karban has authored 31 papers receiving a total of 300 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Genetics, 12 papers in Pathology and Forensic Medicine and 12 papers in Immunology. Recurrent topics in Josef Karban's work include Chronic Lymphocytic Leukemia Research (22 papers), Lymphoma Diagnosis and Treatment (12 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Josef Karban is often cited by papers focused on Chronic Lymphocytic Leukemia Research (22 papers), Lymphoma Diagnosis and Treatment (12 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Josef Karban collaborates with scholars based in Czechia, United States and Germany. Josef Karban's co-authors include Marek Trněný, Adéla Berková, Tomáš Stopka, K Michalová, Zuzana Zemanová, Jana Březinová, Jiřı́ Mayer, Petra Bašová, Juraj Kokavec and Filipp Savvulidi and has published in prestigious journals such as Blood, Journal of Cellular Physiology and European Journal Of Haematology.

In The Last Decade

Josef Karban

29 papers receiving 297 citations

Peers

Josef Karban
Irina Idler Germany
Hannelore Madle Germany
Kerstin Dietze Germany
Isabel Romero-Camarero Spain
Pamela Ranghetti Italy
Zhi‐Jian Zou China
Tuija Lundán Finland
Svetlana Harder Germany
Stefanie Bug Germany
F Davi France
Irina Idler Germany
Josef Karban
Citations per year, relative to Josef Karban Josef Karban (= 1×) peers Irina Idler

Countries citing papers authored by Josef Karban

Since Specialization
Citations

This map shows the geographic impact of Josef Karban's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josef Karban with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josef Karban more than expected).

Fields of papers citing papers by Josef Karban

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Josef Karban. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josef Karban. The network helps show where Josef Karban may publish in the future.

Co-authorship network of co-authors of Josef Karban

This figure shows the co-authorship network connecting the top 25 collaborators of Josef Karban. A scholar is included among the top collaborators of Josef Karban based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josef Karban. Josef Karban is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Smetana, Karel, et al.. (2023). Technical Note Cell Dysplasia – Cell Dysplastic Features (A Morphological Note). Folia Biologica. 69(1). 34–39.
2.
3.
Vodička, Pavel, Andrea Janíková, Vít Procházka, et al.. (2021). POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA IN THE REAL WORLD. Hematological Oncology. 39(S2). 2 indexed citations
4.
5.
Špaček, Martin, Petra Obrtlíková, Josef Karban, et al.. (2019). Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab. Leukemia Research. 79. 17–21. 4 indexed citations
6.
Karban, Josef, et al.. (2015). Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas. International Journal of Hematology. 102(4). 441–450. 21 indexed citations
7.
Špaček, Martin, Josef Karban, J Kvasnička, et al.. (2014). CD200 Expression Improves Differential Diagnosis Between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma. Blood. 124(21). 5637–5637. 7 indexed citations
8.
Smetana, Karel, et al.. (2013). Microscopic notes on the perinucleolar chromatin region in immature and mature human B-leukemia lymphocytes. Neoplasma. 60(3). 284–289. 2 indexed citations
9.
Burda, Pavel, Petra Bašová, Vojtěch Kulvait, et al.. (2011). MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood. 117(14). 3816–3825. 117 indexed citations
10.
Smetana, Karel, Josef Karban, & Marek Trněný. (2010). To the nucleolar bodies (nucleoli) in cells of the lymphocytic lineage in patients suffering from B – chronic lymphocytic leukemia. Neoplasma. 57(6). 495–500. 4 indexed citations
11.
Březinová, Jana, Adéla Berková, Zuzana Zemanová, et al.. (2010). Telomere length, molecular cytogenetic findings, and immunophenotypic features in previously untreated patients with B-chronic lymphocytic leukemia. Neoplasma. 57(3). 215–221. 4 indexed citations
12.
13.
14.
Karban, Josef, et al.. (2010). Expression of CD66 in non‐Hodgkin lymphomas and multiple myeloma. European Journal Of Haematology. 85(6). 496–501. 8 indexed citations
15.
Berková, Adéla, Zuzana Zemanová, Marek Trněný, et al.. (2009). Clonal evolution in chronic lymphocytic leukemia studied by interphase fluorescence in-situ hybridization. Neoplasma. 56(5). 455–458. 19 indexed citations
16.
Michalová, K, Zuzana Zemanová, Jana Březinová, et al.. (2005). Incidence of chromosomal anomalies detected with FISH and their clinical correlations in B-chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics. 160(1). 27–34. 31 indexed citations
17.
Černý, Jan, et al.. (2003). Biallelic IgH rearrangements in patients with indolent lymphoproliferative disorders: Molecular and practical implications. Journal of Cellular Physiology. 199(2). 217–226. 9 indexed citations
18.
Michalová, K, et al.. (2003). [Lymphocyte immunophenotyping and cytogenetics for more precise prognosis in patients with type B chronic lymphatic leukemia].. PubMed. 142(2). 106–11. 2 indexed citations
19.
Michalová, K, et al.. (2002). [Importance of prognostic factors in patients with chronic B-lymphocytic leukemia at the time of diagnosis].. PubMed. 103(3). 359–70. 5 indexed citations
20.
Michalová, K, et al.. (2000). [The interphase fluorescence in situ hybridization (I-FISH) technique in patients with chronic lymphatic leukemia (CLL)].. PubMed. 139(11). 334–8. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Irina Idler Breakdown of academic impact, for papers by Hannelore Madle Breakdown of academic impact, for papers by Kerstin Dietze Breakdown of academic impact, for papers by Isabel Romero-Camarero Breakdown of academic impact, for papers by Pamela Ranghetti Breakdown of academic impact, for papers by Zhi‐Jian Zou Breakdown of academic impact, for papers by Tuija Lundán Breakdown of academic impact, for papers by Svetlana Harder Breakdown of academic impact, for papers by Stefanie Bug Breakdown of academic impact, for papers by F Davi
Rankless by CCL
2026